Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Pinpoint accuracy: programmable nanoparticles and future cancer treatments

Most cancer drugs are not as effective as doctors would like them to be because the amount that can be administered is limited by toxicity. But a new technology, Accurin, which utilises programmable nanoparticles, is set to change all that. Elly Earls sits down with BIND Biosciences CEO Scott Minick to find out how this targeted nanotherapeutic could mark the beginning of a new era in cancer therapy.

Go Top